Hsu CH - Search Results

1

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.

Liu TH, Chen SC, Rau KM, Lu LC, Lin PT, Su YY, Teng W, Lai SW, Yeh RH, Kao TM, Lee PC, Wu CJ, Chen CH, Hsu CH, Lin SM, Huang YH, Chen LT, Cheng AL, Shen YC; Taiwan Liver Cancer Association Research Group (TRG). Liu TH, et al. Among authors: hsu ch. Liver Cancer. 2024 Feb 1;13(5):509-521. doi: 10.1159/000536549. eCollection 2024 Oct. Liver Cancer. 2024. PMID: 39435270 Free PMC article.

2

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.

Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Shao YY, et al. Among authors: hsu c, hsu ch. Cancer. 2010 Oct 1;116(19):4590-6. doi: 10.1002/cncr.25257. Cancer. 2010. PMID: 20572033 Free article.

3

Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Shao YY, Hsu CH, Cheng AL. Shao YY, et al. Among authors: hsu ch. Liver Cancer. 2013 Apr;2(2):93-107. doi: 10.1159/000343845. Liver Cancer. 2013. PMID: 24159601 Free PMC article. Review.

4

Clinical trials in hepatocellular carcinoma: an update.

Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Shen YC, et al. Among authors: hsu c, hsu ch. Liver Cancer. 2013 Aug;2(3-4):345-64. doi: 10.1159/000343850. Liver Cancer. 2013. PMID: 24400222 Free PMC article. Review.

5

Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges.

Lu LC, Hsu CH, Hsu C, Cheng AL. Lu LC, et al. Among authors: hsu c, hsu ch. Liver Cancer. 2016 Apr;5(2):128-38. doi: 10.1159/000367754. Epub 2016 Mar 17. Liver Cancer. 2016. PMID: 27386431 Free PMC article. Review.

6

Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure.

Liu TH, Hsu CH, Shao YY. Liu TH, et al. Among authors: hsu ch. Liver Cancer. 2018 May;7(2):205-208. doi: 10.1159/000486763. Epub 2018 Apr 20. Liver Cancer. 2018. PMID: 29888209 Free PMC article. No abstract available.

7

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment.

Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH. Lu LC, et al. Among authors: hsu ch. Liver Cancer. 2019 Mar;8(2):110-120. doi: 10.1159/000489021. Epub 2018 Jun 15. Liver Cancer. 2019. PMID: 31019901 Free PMC article.

8

Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.

Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ, Cheng AL, Hsu CH. Shao YY, et al. Among authors: hsu c, hsu ch. Liver Int. 2019 Nov;39(11):2184-2189. doi: 10.1111/liv.14210. Epub 2019 Aug 31. Liver Int. 2019. PMID: 31400295

9

Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, Hung YP, Chang CJ, Shen YC, Guo JC, Liu TH, Hsu CH, Cheng AL. Lu LC, et al. Among authors: hsu c, hsu ch. Liver Cancer. 2019 Nov;8(6):480-490. doi: 10.1159/000501275. Epub 2019 Aug 6. Liver Cancer. 2019. PMID: 31799205 Free PMC article.

10

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review.

Hsu CH, Huang YH, Lin SM, Hsu C. Hsu CH, et al. Among authors: hsu c. Liver Cancer. 2022 Feb 10;11(2):94-112. doi: 10.1159/000520501. eCollection 2022 Apr. Liver Cancer. 2022. PMID: 35634427 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,384 results

Search Page

Filters